Neuro Pharmacology - Depression and Anxiety

Descripción

KUSOP Pharmacology III "Sample Questions"
Ifeoma Okekearu
Test por Ifeoma Okekearu, actualizado hace más de 1 año
Ifeoma Okekearu
Creado por Ifeoma Okekearu hace alrededor de 9 años
56
3

Resumen del Recurso

Pregunta 1

Pregunta
Activation of the thalamus can activate the innate fear pathway. Without the collaboration of the prefrontal cortex, this activation can lead to fear manifestations without a source.
Respuesta
  • True
  • False

Pregunta 2

Pregunta
Which of the following statements about the manifestation of anxiety/fear symptoms is not true?
Respuesta
  • Lesions of the medical prefrontal cortex increases the risk for anxiety.
  • Inhibition of the orbitofrontal cortex leads to the hyperactivity of the amygdala in the presence of a potential threat which produces fear responses.
  • In the innate fear response, the thalamus is activated by the amygdala with sequential prefrontal cortex activation leading to the fear manifestation.
  • The amygdala mediates key functions in the processing of fear and threat-related information.

Pregunta 3

Pregunta
Select all of the options that are effective in the treatment of anxiety disorder
Respuesta
  • Relaxation Training
  • Systematic Desensitization
  • Group Therapy
  • Pharmacotherapy

Pregunta 4

Pregunta
Select the statements about the tuberomamillary nucleus that are true
Respuesta
  • It is inhibited by GABA from the ventrolateral pre optic area.
  • It is activated by glutamate
  • It is inhibited by orexin
  • Histamine promotes calm wakefulness through H2 receptors

Pregunta 5

Pregunta
Where to benzodiazepines bind and what is their mechanism of action?
Respuesta
  • They bind to a niche between the α and γ subunits of the GABAa receptors behaving as GABA agonist
  • They bing to the niche between the α and γ subunits of the GABAb receptors acting as a positive allosteric modulator
  • They bind to a niche between the α and γ subunits of the GABAa receptors behaving as positive allosteric modulators
  • They bing to the niche between the α and γ subunits of the GABAb receptors acting as a GABA agonist

Pregunta 6

Pregunta
Positive modulation of the GABAa receptors of the amygdala will produce a hypnotic effect
Respuesta
  • True
  • False

Pregunta 7

Pregunta
Flumenazil is a GABA antaagonist
Respuesta
  • True
  • False

Pregunta 8

Pregunta
Which anti-xiolitic(s) would be a good choice for an elderly patient?
Respuesta
  • Lorazepam
  • Temazepam
  • Diazepam
  • Chlordiazepoxide

Pregunta 9

Pregunta
Drugs binding to α1, α2, α3, α5, and γ subunits of the GABAa synaptic receptor mediate phasic inhibition triggered by peak concentrations of GABA predisposing users to dependence.
Respuesta
  • True
  • False

Pregunta 10

Pregunta
What is the recommended rate of reduction for people wanting to discontinue the use of benzodiazepines?
Respuesta
  • Stop immediately and drink a lot of water
  • Flumenazil injections over the course of 5-7 days
  • Decrease by 10 percent each day
  • None of the above responses are correct

Pregunta 11

Pregunta
Barbiturates produce an anti-xiolitic effect by binding to the β subunit of the GABA-a receptor. At high concentrations, they can mimic GABA and directly activate chloride channels.
Respuesta
  • True
  • False

Pregunta 12

Pregunta
Overdose of barbiturates can lead to death due to respiratory and cardiac depression and the lack of an effective antagonist.
Respuesta
  • True
  • False

Pregunta 13

Pregunta
Monoamine Oxidase Inhibitors are Indicated for use with Barbiturates because they shorten the length of action, decreasing side effects.
Respuesta
  • True
  • False

Pregunta 14

Pregunta
What statement below is accurate regarding the changes the amounts of BDNF in the brain of depressed patients?
Respuesta
  • There is an INCREASE in the amount of BDNF in the Hippocampus and a DECREASE in the amount of BDNF in the Nucleus Accumbens
  • There is an INCREASE in the amount of BDNF in BOTH the Hippocampus and the Nucleus Accumbens.
  • There is a DECREASE in the amount of BDNF in BOTH the Hippocampus and the Nucleus Accumbens.
  • There is a DECREASE in the amount of BDNF in the Hippocampus and an INCREASE in the amount of BDNF in the Nucleus Accumbens.

Pregunta 15

Pregunta
Which class of anti-depressants cause the "Cheese Effect"
Respuesta
  • MAOIs
  • SSRIs
  • NMDA Blockers
  • SNRIs
Mostrar resumen completo Ocultar resumen completo

Similar

Monoamine pharmacology -Antidepressant drugs - Dr. Emma Robinson
Anna mph
Drug absorption, distribution, metabolism and excretion
Hannah Tribe
Neuro anatomy
James Murdoch
Exam 1 Medications
tera_alise
Pharmacology
Justin Veazey
Neuro-Cognitive Disorders
SaraJaarour
Cognition and Dementia - Alzheimer's disease.
Anna mph
NCLEX REVIEW MODEL
Jamie R Pascual
General Anaesthetics Part 1 - Steve Fitzjohn
Anna mph
G- Couple Protein Receptors
Has Maj
Transcription
Has Maj